Satricabtagene autoleucel

舒瑞基奥仑赛

Report date: 2025/07/02 16:43:02

Base Information

Drug NameSatricabtagene autoleucel
Drug Alias NameCAR-CLD18 T-cell人源化抗Claudin18.2 (CLDN18.2)自体CAR T细胞Autologous humanized anti-claudin18.2 chimeric antigen receptor T cellSatri-celClaudin18.2-redirected Autologous Cells +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatitis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPeking UniversityCARsgen Therapeutics Holdings LtdCarsgen Biomedicine (Shanghai) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatitis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A